<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="82833">
  <stage>Registered</stage>
  <submitdate>20/05/2008</submitdate>
  <approvaldate>28/05/2008</approvaldate>
  <actrnumber>ACTRN12608000269336</actrnumber>
  <trial_identification>
    <studytitle>A single blinded, randomised study to compare efficacy and acceptability of magnesium sulfate capsules (Colocap: Balance) with sodium picosulfate (Pharmatel Fresenius Kabi: Picoprep) for bowel cleansing prior to colonoscopy.</studytitle>
    <scientifictitle>A single blinded, randomised study to compare efficacy and acceptability of magnesium sulfate capsules (Colocap: Balance) with sodium picosulfate (Pharmatel Fresenius Kabi: Picoprep) for bowel cleansing prior to colonoscopy.</scientifictitle>
    <utrn />
    <trialacronym />
  </trial_identification>
  <conditions>
    <healthcondition>Colonoscopy</healthcondition>
    <conditioncode>
      <conditioncode1>Oral and Gastrointestinal</conditioncode1>
      <conditioncode2>Normal oral and gastrointestinal development and function</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Magnesium sulfate, encapsulated (65 capsules), total 61.75g (Colocap Balance), single administration before the procedure</interventions>
    <comparator>Sodium picosulfate, powder, 3 sachets (Picoprep), single administration before the procedure</comparator>
    <control>Active</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>To evaluate the efficacy of 65 capsules of magnesium sulfate compared with 3 sachets of sodium picosulfate using the clinician's blinded evaluation of the quality of the bowel clean using the validated Ottawa Bowel Preparation Score</outcome>
      <timepoint>During the colonoscopy procedure</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>To evaluate patients' assessment of overall acceptability of magnesium sulfate compared with sodium picosulfate using their reports of palatability, ease of use (compliance) and tolerability (side effects) using a patient-completed assessment form.</outcome>
      <timepoint>After taking the bowel preparation, before the colonoscopy procedure</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Presenting for elective colonoscopy</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>Not stated</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Renal insufficiency, current chronic inflammatory bowel disease</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Diagnosis</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Each Investigator will be assigned a group of numbered patient kits, each pre-packed according to the randomisation schedule with either instructions on how to take sodium picosulfate or magnesium sulfate.  Each new enrolling patient will be allocated the next sequential patient pack.  A third person (practice manager, nurse etc) will check the contents of the pack to see which treatment/medication should be provided to the patient. Patients and practice managers will be told not to discuss treatment with their doctors at any stage.  Doctors will explain both treatments in detail during the consenting process.</concealment>
    <sequence>Computer generated randomised numbers</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate>1/06/2008</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>400</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Closed: follow-up continuing</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Colocap Pharmaceuticals</primarysponsorname>
    <primarysponsoraddress>Unit 7, 176 Main Street
Osborne Park WA 6017</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Colocap Pharmaceuticals</fundingname>
      <fundingaddress>Unit 7, 176 Main Street
Osborne Park WA 6017</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary />
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>St John of God Health Care Ethics Committee</ethicname>
      <ethicaddress>Level 3, St John of God House
177-179 Cambridge St
Subiaco WA 6008</ethicaddress>
      <ethicapprovaldate>4/04/2008</ethicapprovaldate>
      <hrec>EC00286</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Dr Leon Levitt</name>
      <address>Colocap Pharmaceuticals
Unit 7, 176 Main Street
Osborne Park  WA  6017</address>
      <phone>(08) 9349 2700</phone>
      <fax>(08) 9349 2711</fax>
      <email>leon@colocap.com.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Shannon Meyerkort</name>
      <address>Colocap Pharmaceuticals
Unit 7, 176 Main Street
Osborne Park  WA  6017</address>
      <phone>(08) 9349 2700</phone>
      <fax>(08) 9349 2711</fax>
      <email>shannon@colocap.com.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Shannon Meyerkort</name>
      <address>Colocap Pharmaceuticals
Unit 7, 176 Main Street
Osborne Park  WA  6017</address>
      <phone>(08) 9349 2700</phone>
      <fax>(08) 9349 2711</fax>
      <email>shannon@colocap.com.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>